Department of Gastroenterology, Shanghai First People's Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China.
J Clin Transl Hepatol. 2014 Sep;2(3):197-201. doi: 10.14218/JCTH.2014.00022. Epub 2014 Sep 15.
Hepatitis B virus (HBV) infection is a leading cause of liver disease worldwide, with 75% of those affected distributed in the Asia-Pacific region. Approximately one million HBV-infected patients die of liver cirrhosis and hepatocellular carcinoma (HCC) each year. If left untreated, 6-20% of chronic hepatitis B (CHB) patients will develop cirrhosis over five years. The cumulative incidence of HBV-related cirrhosis, disease progression, and prognosis are closely associated with serum HBV DNA levels. Antiviral therapy in HBV-related cirrhosis has been documented by several long-term cohort studies to decrease disease progression to hepatic decompensation and HCC. The approval and availability of oral antiviral agents with better safety profiles has greatly improved the prognosis for HBV-related cirrhosis. Here, we discuss the significance of antiviral therapy for HBV-related cirrhosis and the management of HBV-related diseases in the future.
乙型肝炎病毒（HBV）感染是全球范围内导致肝脏疾病的主要原因，其中 75%的感染者分布在亚太地区。每年约有 100 万 HBV 感染者死于肝硬化和肝细胞癌（HCC）。未经治疗，6-20%的慢性乙型肝炎（CHB）患者在五年内会发展为肝硬化。HBV 相关肝硬化、疾病进展和预后的累积发生率与血清 HBV DNA 水平密切相关。几项长期队列研究证明，HBV 相关肝硬化的抗病毒治疗可降低肝失代偿和 HCC 的疾病进展。具有更好安全性特征的口服抗病毒药物的批准和可用性极大地改善了 HBV 相关肝硬化的预后。在这里，我们讨论了抗病毒治疗 HBV 相关肝硬化的意义以及未来 HBV 相关疾病的管理。
